Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
174
resultados
Última actualización
07/06/2025 [06:57:00]
Resumen de: WO2025117512A1
A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.
Resumen de: AU2025203521A1
The present disclosure provides a continuous glucose monitoring device. The continuous glucose monitoring device comprises a body attachable unit configured to attach to a body; an applicator accommodating the body attachable unit, the applicator configured to guide the body attachable unit to be mounted on the body based on manipulation of a user; a housing comprising an inner case and an outer case; a plunger body movably disposed in the housing and configured to move from a first position to a second position along an insertion direction; a needle unit coupled to the plunger body; and a rotatable body being rotated based on a movement of the plunger body. The rotatable body is rotated when the plunger body moves from the first position to the second position. The rotatable body is positioned between the inner case and the plunger body to block movement of the plunger body in a withdrawal direction opposite to the insertion direction when the plunger body reaches the second position.
Resumen de: AU2025203519A1
The present disclosure is directed to a composite implant for the sustained release of a therapeutic agent from a hydrogel matrix. The hydrogel matrix may be a cross-linked bioerodible polyethylene glycol (PEG) hydrogel with a therapeutic complex dispersed within the cross-linked bioerodible PEG hydrogel. The therapeutic complex may include a therapeutic agent in association with mesoporous silica particles. The composite implant is configured to be delivered to or implanted into an eye of a subject or patient. The composite implant may be used treat ocular disease in a subject or patient. Ocular diseases may be selected from at least one of neovascular age related macular degeneration (AMD), diabetic macular edema, or macular edema following retinal vein occlusion.
Resumen de: WO2025117940A1
Blood plasma samples are obtained from type 2 diabetes (T2D) patients and a concentration of F2-isoprostanes (F2I) in the sample is quantified. Plasma F2I levels assess oxidative stress levels in the patient and indicate elevated risk of T2D-associated complications including incident clinical fracture, cardiovascular complications, renal disease, etc. in the T2D cohort, independently of other risk factors. Fracture risk in the T2D population is heightened for a given bone mineral density (BMD) and is underestimated by evaluation tools such as Fracture Risk Assessment Tool (FRAX). The patient's BMD T-score can be adjusted based on F2I concentrations, capturing reductions in bone quality as well as quantity that lead to the elevated fracture risk in T2D patients. These diagnostic procedures can be effectively deployed in a patient's course of treatment merely by supplementing an existing blood panel, rather than with a separate blood draw.
Resumen de: WO2025117463A1
Disclosed herein are systems and methods for closed loop and/or partial and/or hybrid closed loop therapy that can provide adaptive personal profiles for when glucose levels are not available and/or unreliable from a continuous glucose monitor (CGM), such as, for example, during a warmup period of the CGM sensor. The profile can include temporary delivery profile such as a CGM warmup profile that is activated specifically for the particular scenario and is designed to minimize the risk of blood glucose fluctuations until the glucose levels are available and reliable, such as when the CGM sensor is warmup up and closed loop therapy based on the sensor can be activated.
Resumen de: WO2025117799A1
Embodiments described herein gradually shift a basal rate pattern for a user in time when the time on an insulin pump is changed and use glucose levels from a CGM sensor to coordinate the shift in the basal pattern with the user's actual glucose response to the changing parameters to safely transition the timing of the basal pattern as quickly as possible.
Resumen de: WO2025116761A1
The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of wrist-worn devices for this purpose, as well as in the creation of socially-oriented systems for the early diagnosis of diabetes and associated diseases in the form of wrist-worn devices. The aim of the invention is to improve the operational efficiency of a wrist-worn device for non-invasively checking a person's blood glucose concentration by reducing the preparation and configuration time required. The technical result of the invention is that of reducing preparation and configuration time and, in general, reducing the time taken to perform a non-invasive check of a person's blood glucose concentration by preventing a mobile unit from moving with or along a wrist strap in relation to the radial artery of a person's arm when the person is walking or using the arm on which the device is worn.
Resumen de: WO2025116766A1
The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of sensors for non-invasively checking a person's blood glucose concentration. The aim of the invention is to improve the operational efficiency of a sensor for a wrist-worn device for non-invasively checking a person's blood glucose concentration by reducing the preparation and configuration time required. The technical results of the invention include: increasing the adhesive force between a rim and the arm of a person by increasing the contact area between said rim and a wet or dry surface of the arm; reducing the energy spent on non-invasively checking a person's blood glucose concentration; and increasing the heat transfer of the sensor via the crest of the rim to the person's arm by increasing the contact area between the rim and the arm.
Resumen de: WO2025116762A1
The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of sensors for non-invasively checking a person's blood glucose concentration, as well as in the creation of socially-oriented systems for the early diagnosis of diabetes and associated diseases. The aim of the invention is to improve the operational efficiency of a sensor for a wrist-worn device for non-invasively checking a person's blood glucose concentration by reducing the operational energy consumption of the sensor by virtue of the shape of the inner surface of a rim. The technical result of the invention is that of reducing the operational energy consumption of the sensor. This reduction is achieved by virtue of the shape of the inner surface of a rim, which results in an increase in the amount of light reflected from the arm, and specifically from an artery and other vessels in the arm, and impinging on a light receiver.
Resumen de: WO2025116086A1
The present invention relates to technology for measuring blood glucose and glycated hemoglobin using a non-invasive PPG sensor and, more specifically, to a method and an apparatus for measuring blood glucose and glycated hemoglobin by using artificial intelligence technology in which pulse wave signals of a measurer are sensed using a PPG (pulse wave) sensor and analyzed by a machine learning algorithm to estimate blood glucose and glycated hemoglobin levels.
Resumen de: US2025176868A1
A method of calculating at least one physiological parameter using a reticulocyte production index (RPI) value can include: measuring a plurality of first glucose levels over a first time period; measuring a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; measuring the RPI value; calculating a red blood cell elimination constant (kage) based on the RPI value; and calculating the at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (kgly), a red blood cell generation rate constant (kgen), and an apparent glycation constant (K), based on (1) the plurality of first glucose levels, (2) the first HbA1c level, and (3) the kage. Further, one or more related analyses (e.g., personalized-target glucose range, personalized-target average glucose, cHbA1c, and the like) can be estimated and/or adjusted based on the at least one physiological parameter.
Resumen de: US2025176870A1
A device for determining a glucose concentration in an anterior chamber of a user's eye includes a VCSEL which emits laser light, and an optical element for influencing the laser light and/or an emergent light. The VCSEL and the optical element are configured such that the laser light enters the anterior chamber of the eye. The emergent light from the anterior chamber penetrates into the VCSEL. The device further includes an analysis unit that analyses a resulting self-mixing interference within the VCSEL to determine the glucose concentration.
Resumen de: US2025176865A1
The proposed invention relates to a method of determining a blood glucose level of a user. The method comprises obtaining, by a Photoplethysmography (PPG) sensor (302), raw data related to pulsations of a user. The raw data is filtered by a Data Signal Processing (DSP) filter to obtain derived variables related to variations in blood viscosity. The raw data is further processed by a probabilistic model to obtain secondary variables related to operating conditions of a circulatory and respiratory system of the user. Readings of the PPG sensor (302) are obtained by a microcontroller (306). The readings of the PPG sensor (302) indicates intensity values of reflections of light transmitted by the PPG sensor onto a blood vessel of the user. The readings of the PPG sensor (302) are processed based on the derived variables and the secondary variables to determine a blood glucose level of the user.
Resumen de: US2025177649A1
A portable insulin pump can integrate and display data from a continuous glucose monitor (CGM) to allow a user to more readily determine whether any interaction with the pump is necessary. Data from the CGM can automatically be transmitted to the pump and can be displayed for user analysis or automatically analyzed to present recommendations to the user based on combined data from the CGM and the pump.
Resumen de: US2025180540A1
A blood glucose measurement device having a display, includes a housing having one or more openings on one side, one or more contact electrodes configured to electrically coupled to a sensor strip inserted into the housing through the one or more openings, one or more control buttons configured to turn on the blood glucose measurement device, and one or more processors configured to control a first execution screen to be displayed in response to receiving a first signal by the one or more contact electrodes and, display a second execution screen in response to receiving a second signal by the one or more control buttons.
Resumen de: US2025180505A1
A glucose biosensor encasement includes a first membrane and a second membrane. The first membrane has a first interlocking segment. The second membrane has a second interlocking segment cooperating with the first interlocking segment of the first membrane to provide a cavity between the first membrane and the second membrane configured to receive a glucose sensor. At least one of the first membrane and the second membrane comprises a semi-permeable portion configured to regulate diffusion characteristics of glucose through the membrane to realize a sensitivity for a sensor in the cavity. A method is also provided.
Resumen de: US2025182875A1
An apparatus comprising a controller. The controller includes an input/output (I/O) module and a rule module. The I/O module is configured to present a question for a patient when communicatively coupled to a user interface and receive patient information in response to the question via the user interface. The rule module is configured to apply a rule to the patient information and generate a suggested insulin pump setting from application of the rule. Other devices, systems, and methods are disclosed.
Resumen de: US2025182874A1
An insulin delivery supervisor (IDS) with a safety analysis and supervision function that can reside between the insulin request and the insulin delivery and can intercept any excessive insulin requests before the insulin was delivered. The IDS can be implemented in any system based on insulin pump or pen and will work with either SMBG or CGM modes of blood glucose monitoring.
Resumen de: AU2023312740A1
Systems, devices and methods are provided for incorporating a medication delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. The integrated management system may produce a plurality of reports that may include data related to analyte levels (e.g., glucose levels) and medication delivered (e.g., insulin delivered). The medication delivery device may also provide feedback to the user.
Resumen de: US12318218B1
A computer-implemented method improves efficacy of diabetes self-management to obtain a measurement message and/or contextual activity information used to determine a suitable insulin dosage to treat a patient. The method includes simulating a health coach in a natural conversation to obtain a measurement of the patient's blood-glucose level, processing the measured blood-glucose level with a personalized insulin titration algorithm to determine an insulin dosage recommendation, and generating an electronic signal configured to cause a corresponding action to be performed by a computing device.
Resumen de: WO2025109398A1
Non-enzymatic electrochemical glucose sensor (100), for the detection of glucose in biological fluids, characterized in comprising: - a support (101), having a first surface and a second surface opposite to the first surface; - a first metallic electrode (102a), a second metallic electrode (102b), and a third metallic electrode (102c) deposited on said support (101); - a sensitive element consisting of a compound, having a nanoporous structure, deposited on a surface of the second metallic electrode (102b). The invention is also related to a fabrication process of the non-enzymatic electrochemical glucose sensor (100).
Resumen de: AU2025203317A1
Systems, devices, and methods are disclosed for wireless communication of analyte data. One such method includes, during a first interval, establishing a first connection between an analyte sensor system and a display device. During the first connection, the method includes exchanging information related to authentication between the analyte sensor system and the display device. The method includes making a determination regarding whether authentication was performed during the first interval. During a second interval, the method may include establishing a second connection between the analyte sensor system and the display device for transmission of an encrypted analyte value, and bypassing the exchanging of information related to authentication performed during the first connection. The method also includes, during the second interval, the analyte sensor system transmitting the encrypted analyte value to the display device, if the determination indicates that the authentication was performed during the first interval.
Resumen de: AU2025203318A1
Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method of using a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device.
Resumen de: US2025172539A1
Techniques for data processing and control for a glucose monitoring system are provided, including obtaining a first sensitivity of a glucose sensor; obtaining a second sensitivity of the glucose sensor; comparing a difference between the first sensitivity and the second sensitivity to a predetermined range of values; if the difference is outside the predetermined range of the values, causing a calibration routine for the glucose sensor to be performed; and if the difference is within the predetermined range of values determining a composite sensitivity for a current calibration of the glucose sensor based on the first sensitivity and the second sensitivity and calculating the glucose level based on the current calibration of the glucose sensor.
Nº publicación: US2025172566A1 29/05/2025
Solicitante:
CARBOMETRICS LTD [GB]
CARBOMETRICS LIMITED
Resumen de: US2025172566A1
The present invention relates to saccharide sensing systems including macrocyclic compounds which are capable of binding to a target saccharide (e.g. glucose) and a detectable reporter for providing a detectable signal based on the binding of the target saccharide by the macrocyclic compound.
BOPI
Sede Electrónica
